Initiator Pharma: Positive Phase IIb results

Research Update



Redeye provides a short research update following the positive phase IIb results with lead candidate pudafensine published by Initiator Pharma last week. Overall, we are encouraged to learn that the candidate demonstrated statistically significant and clinically relevant efficacy. We raise our base case valuation to SEK24 as we see an increased likelihood of approval (LoA) following the results.



Kevin Sule

Fredrik Thor

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.